About Kynureninase
Kynureninase (KYNU) is a protein
from Homo sapiens identified by UniProt accession
Q16719, 465 residues long.
MolForge cross-references it against 0 known binders and
262 disease associations.
Target properties
| Protein name | Kynureninase |
| UniProt accession | Q16719 |
| Gene | KYNU |
| Organism | Homo sapiens |
| Length | 465 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (262)
Diseases linked to this target (Open Targets).
- vertebral, cardiac, renal, and limb defects syndrome 2 · score 0.73
- congenital vertebral-cardiac-renal anomalies syndrome · score 0.61
- encephalopathy due to hydroxykynureninuria · score 0.53
- Catel-Manzke syndrome · score 0.48
- cataract · score 0.41
- blood protein measurement · score 0.41
- neurodegenerative disease · score 0.37
- lymphocyte count · score 0.37
- platelet count · score 0.35
- total blood protein measurement · score 0.31
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q16719-F1 | alphafold | PREDICTED | 95.43 | — |
Amino-acid sequence (465 residues)
MEPSSLELPA DTVQRIAAEL KCHPTDERVA LHLDEEDKLR HFRECFYIPK IQDLPPVDLS LVNKDENAIY FLGNSLGLQP KMVKTYLEEE LDKWAKIAAY GHEVGKRPWI TGDESIVGLM KDIVGANEKE IALMNALTVN LHLLMLSFFK PTPKRYKILL EAKAFPSDHY AIESQLQLHG LNIEESMRMI KPREGEETLR IEDILEVIEK EGDSIAVILF SGVHFYTGQH FNIPAITKAG QAKGCYVGFD LAHAVGNVEL YLHDWGVDFA CWCSYKYLNA GAGGIAGAFI HEKHAHTIKP ALVGWFGHEL STRFKMDNKL QLIPGVCGFR ISNPPILLVC SLHASLEIFK QATMKALRKK SVLLTGYLEY LIKHNYGKDK AATKKPVVNI ITPSHVEERG CQLTITFSVP NKDVFQELEK RGVVCDKRNP NGIRVAPVPL YNSFHDVYKF TNLLTSILDS AETKN
Explore Kynureninase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets